NCT06500208View on ClinicalTrials.gov

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide

Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER